drugset / Trial / NCT06709859
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, single-arm study to evaluate the efficacy and safety of Afatinib plus chemotherapy as conversion treatment in patients with unresectable EGFR sensitive mutation-positive stage III non-small cell lung cancer.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2026-05-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | — |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |